The company’s economic evaluation compared the cost effectiveness of onasemnogene abeparvovec versus BSC for treating patients with pre-symptomatic SMA and two or three copies of the SMN2 gene. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.